- Home
- Publications
- Publication Search
- Publication Details
Title
Recent advances in CAR-T cell engineering
Authors
Keywords
-
Journal
Journal of Hematology & Oncology
Volume 13, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-07-02
DOI
10.1186/s13045-020-00910-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- On Site Manufacture of AntiCD19 CAR-T Cells. Responses in Subjects with Rapidly Progressive Refractory Lymphomas.
- (2020) Paolo Caimi et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Durable Remission Following “Off-the-Shelf” Chimeric Antigen Receptor (CAR) T-Cells in Patients with Relapse/Refractory (R/R) B-Cell Malignancies
- (2020) Kevin J. Curran et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Phase 1/2 Study of AUTO3 the First Bicistronic Chimeric Antigen Receptor (CAR) Targeting CD19 and CD22 Followed By an Anti-PD1 in Patients with Relapsed/Refractory (r/r) Diffuse Large B Cell Lymphoma (DLBCL): Results of Cohort 1 and 2 of the Alexander Study
- (2020) Kirit M. Ardeshna et al. BLOOD
- A Bispecific CAR-T Cell Therapy Targeting Bcma and CD38 for Relapsed/Refractory Multiple Myeloma: Updated Results from a Phase 1 Dose-Climbing Trial
- (2020) Chenggong Li et al. BLOOD
- Phase I Trial Using CD19/CD22 Bispecific CAR T Cells in Pediatric and Adult Acute Lymphoblastic Leukemia (ALL)
- (2020) Liora M Schultz et al. BLOOD
- A Novel CD19-Anti-CD20 Bridging Protein Prevents and Reverses CD19-Negative Relapse from CAR19 T Cell Treatment In Vivo
- (2020) Paul Rennert et al. BLOOD
- FT596: Translation of First-of-Kind Multi-Antigen Targeted Off-the-Shelf CAR-NK Cell with Engineered Persistence for the Treatment of B Cell Malignancies
- (2020) Jode P Goodridge et al. BLOOD
- Anti-CD19/CD22 Dual CAR-T Therapy for Refractory and Relapsed B-Cell Acute Lymphoblastic Leukemia
- (2020) Junfang Yang et al. BLOOD
- CXCR2‐modified CAR‐T cells have enhanced trafficking ability that improves treatment of hepatocellular carcinoma
- (2020) Guangna Liu et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Sustained, cell-intrinsic versus intermittent, cell-extrinsic checkpoint blockade in solid tumor CAR T-cell therapy.
- (2020) Camille Linot et al. JOURNAL OF CLINICAL ONCOLOGY
- Anti–B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma
- (2020) Max S. Topp et al. JOURNAL OF CLINICAL ONCOLOGY
- Interleukin-23 engineering improves CAR T cell function in solid tumors
- (2020) Xingcong Ma et al. NATURE BIOTECHNOLOGY
- Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors
- (2020) Enli Liu et al. NEW ENGLAND JOURNAL OF MEDICINE
- EGFRvIII-CAR-T Cells with PD-1 Knockout Have Improved Anti-Glioma Activity
- (2020) Haifeng Zhu et al. PATHOLOGY & ONCOLOGY RESEARCH
- Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia
- (2020) Hanren Dai et al. Journal of Hematology & Oncology
- Eradication of neuroblastoma by T cells redirected with an optimized GD2-specific chimeric antigen receptor and interleukin-15
- (2019) Yuhui Chen et al. CLINICAL CANCER RESEARCH
- Delayed remission following sequential infusion of humanized CD19- and CD22-modified CAR-T cells in a patient with relapsed/refractory acute lymphoblastic leukemia and prior exposure to murine-derived CD19-directed CAR-T cells
- (2019) Fei Yang et al. OncoTargets and Therapy
- NR4A transcription factors limit CAR T cell function in solid tumours
- (2019) Joyce Chen et al. NATURE
- Clinical trials of dual-target CAR T cells, donor-derived CAR T cells, and universal CAR T cells for acute lymphoid leukemia
- (2019) Juanjuan Zhao et al. Journal of Hematology & Oncology
- PD-1 Blockade with Pembrolizumab for Classical Hodgkin Lymphoma after Autologous Stem Cell Transplantation
- (2019) Philippe Armand et al. BLOOD
- 8CD19 Chimeric Antigen Receptor (CAR) Engineered Epstein-Barr Virus (EBV) Specific T cells – An Off-the-Shelf, Allogeneic CAR T-Cell Immunotherapy Platform
- (2019) R.R. Shen et al. CYTOTHERAPY
- 1MATCHED SIBLING DONOR-DERIVED PIGGYBAC CAR19 T CELLS INDUCE REMISSION OF RELAPSED/REFRACTORY CD19+ MALIGNANCY FOLLOWING HAEMATOPOIETIC STEM CELL TRANSPLANT
- (2019) D.C. Bishop et al. CYTOTHERAPY
- Phase 1 trial of anti-CD19 chimeric antigen receptor T (CAR-T) cells with tumor necrosis alfa receptor superfamily 19 (TNFRSF19) transmembrane domain.
- (2019) Paolo Fabrizio Caimi et al. JOURNAL OF CLINICAL ONCOLOGY
- 2B4 costimulatory domain enhancing cytotoxic ability of anti-CD5 chimeric antigen receptor engineered natural killer cells against T cell malignancies
- (2019) Yingxi Xu et al. Journal of Hematology & Oncology
- A safe and potent anti-CD19 CAR T cell therapy
- (2019) Zhitao Ying et al. NATURE MEDICINE
- Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
- (2019) Noopur Raje et al. NEW ENGLAND JOURNAL OF MEDICINE
- Engineering switchable and programmable universal CARs for CAR T therapy
- (2019) Delong Liu et al. Journal of Hematology & Oncology
- Target selection for CAR-T therapy
- (2019) Jianshu Wei et al. Journal of Hematology & Oncology
- Anti-αFR CAR-engineered NK-92 Cells Display Potent Cytotoxicity Against αFR-positive Ovarian Cancer
- (2019) Xiang Ao et al. JOURNAL OF IMMUNOTHERAPY
- CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity
- (2019) Bryan D. Choi et al. NATURE BIOTECHNOLOGY
- A mathematical model of combined CD8 T cell costimulation by 4-1BB (CD137) and OX40 (CD134) receptors
- (2019) Anna Konstorum et al. Scientific Reports
- An IL-4/21 Inverted Cytokine Receptor Improving CAR-T Cell Potency in Immunosuppressive Solid-Tumor Microenvironment
- (2019) Yi Wang et al. Frontiers in Immunology
- Improved survival of chimeric antigen receptor‐engineered T ( CAR ‐T) and tumor‐specific T cells caused by anti‐programmed cell death protein 1 single‐chain variable fragment‐producing CAR ‐T cells
- (2019) Masao Nakajima et al. CANCER SCIENCE
- PD-1 silencing impairs the anti-tumor function of chimeric antigen receptor modified T cells by inhibiting proliferation activity
- (2019) Jianshu Wei et al. Journal for ImmunoTherapy of Cancer
- Initial Findings of the Phase 1 Trial of PBCAR0191, a CD19 Targeted Allogeneic CAR-T Cell Therapy
- (2019) Caron A. Jacobson et al. BLOOD
- Phase I Study of AUTO3, a Bicistronic Chimeric Antigen Receptor (CAR) T-Cell Therapy Targeting CD19 and CD22, in Pediatric Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (r/r B-ALL): Amelia Study
- (2019) Persis J Amrolia et al. BLOOD
- Highly Efficient Multiplexed Base Editing with Minimized Off-Targets for the Development of Universal CAR-T Cells to Treat Pediatric T-ALL
- (2019) Jason M Gehrke et al. BLOOD
- Manufacture of an Allogeneic CAR-T Stem Cell Memory Product Candidate for Multiple Myeloma, P-Bcma-ALLO1, Is Robust, Reproducible and Highly Scalable
- (2019) Stacey A Cranert et al. BLOOD
- Combination of NKTR-255, a Polymer Conjugated Human IL-15, with CD19 CAR T Cell Immunotherapy in a Preclinical Lymphoma Model
- (2019) Cassie Chou et al. BLOOD
- Enhancing the Effect of CLL-1 CAR T Cells with Interleukin-15 for Treatment of Acute Myeloid Leukemia
- (2019) Pinar Ataca Atilla et al. BLOOD
- Efficacy and Safety of CAR19/22 T-cell "Cocktail" Therapy in Patients with Refractory/ Relapsed B-Cell Malignancies
- (2019) Na Wang et al. BLOOD
- Targeting glycosylation of PD-1 to enhance CAR-T cell cytotoxicity
- (2019) Xiaojuan Shi et al. Journal of Hematology & Oncology
- CAR-T “the living drugs”, immune checkpoint inhibitors, and precision medicine: a new era of cancer therapy
- (2019) Delong Liu Journal of Hematology & Oncology
- Shortened ex vivo manufacturing time of EGFRvIII-specific chimeric antigen receptor (CAR) T cells reduces immune exhaustion and enhances antiglioma therapeutic function
- (2019) Hillary G. Caruso et al. JOURNAL OF NEURO-ONCOLOGY
- Efficacy of third-party chimeric antigen receptor modified peripheral blood natural killer cells for adoptive cell therapy of B-cell precursor acute lymphoblastic leukemia
- (2019) C. Quintarelli et al. LEUKEMIA
- A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial
- (2019) Zhiling Yan et al. Lancet Haematology
- Donor-Derived CD123-Targeted CAR T Cell Serves as a RIC Regimen for Haploidentical Transplantation in a Patient With FUS-ERG+ AML
- (2019) Sun Yao et al. Frontiers in Oncology
- Universal Chimeric Antigen Receptors for Multiplexed and Logical Control of T Cell Responses
- (2018) Jang Hwan Cho et al. CELL
- Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid Leukemia
- (2018) Miriam Y. Kim et al. CELL
- Large-scale expansion of Vγ9Vδ2 T cells with engineered K562 feeder cells in G-Rex vessels and their use as chimeric antigen receptor–modified effector cells
- (2018) Lin Xiao et al. CYTOTHERAPY
- Efficient Non-Viral T-Cell Engineering by Sleeping Beauty Minicircles Diminishing DNA Toxicity and miRNAs Silencing the Endogenous T-Cell Receptors
- (2018) Julian Clauss et al. HUMAN GENE THERAPY
- A novel generation 1928zT2 CAR T cells induce remission in extramedullary relapse of acute lymphoblastic leukemia
- (2018) Jianyu Weng et al. Journal of Hematology & Oncology
- CD19 CAR-T cell therapy for relapsed/refractory acute lymphoblastic leukemia: factors affecting toxicities and long-term efficacies
- (2018) Li-Na Zhang et al. Journal of Hematology & Oncology
- PiggyBac-Engineered T Cells Expressing CD19-Specific CARs that Lack IgG1 Fc Spacers Have Potent Activity against B-ALL Xenografts
- (2018) David C. Bishop et al. MOLECULAR THERAPY
- Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia
- (2018) Joseph A. Fraietta et al. NATURE MEDICINE
- Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
- (2018) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- Extracellular NGFR Spacers Allow Efficient Tracking and Enrichment of Fully Functional CAR-T Cells Co-Expressing a Suicide Gene
- (2018) Monica Casucci et al. Frontiers in Immunology
- Choice of costimulatory domains and of cytokines determines CAR T-cell activity in neuroblastoma
- (2018) Concetta Quintarelli et al. OncoImmunology
- Enhanced Expression of Anti-CD19 Chimeric Antigen Receptor in piggyBac Transposon-Engineered T Cells
- (2018) Daisuke Morita et al. Molecular Therapy-Methods & Clinical Development
- Which is better in CD19 CAR-T treatment of r/r B-ALL, CD28 or 4-1BB? A parallel trial under the same manufacturing process.
- (2018) Peihua Lu et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo
- (2018) Sarwish Rafiq et al. NATURE BIOTECHNOLOGY
- Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell
- (2018) Marco Ruella et al. NATURE MEDICINE
- CAR-T bridging to allo-HSCT as a treatment strategy for relapsed adult acute B-lymphoblastic leukemia: a case report
- (2018) Shupeng Wen et al. BMC CANCER
- CRISPR/Cas9-mediated PD-1 disruption enhances human mesothelin-targeted CAR T cell effector functions
- (2018) Wanghong Hu et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Universal CARs, universal T cells, and universal CAR T cells
- (2018) Juanjuan Zhao et al. Journal of Hematology & Oncology
- Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
- (2018) Frederick L Locke et al. LANCET ONCOLOGY
- CD19-directed CAR T cells gain traction
- (2018) Stephen J Schuster LANCET ONCOLOGY
- Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- (2018) Stephen J. Schuster et al. NEW ENGLAND JOURNAL OF MEDICINE
- Donor origin CAR T cells: graft versus malignancy effect without GVHD, a systematic review
- (2017) Faiz Anwer et al. Immunotherapy
- Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels
- (2017) James N. Kochenderfer et al. JOURNAL OF CLINICAL ONCOLOGY
- Allogeneic CD19-CAR-T cell infusion after allogeneic hematopoietic stem cell transplantation in B cell malignancies
- (2017) Jun Liu et al. Journal of Hematology & Oncology
- Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity
- (2017) E Liu et al. LEUKEMIA
- Avoidance of On-Target Off-Tumor Activation Using a Co-stimulation-Only Chimeric Antigen Receptor
- (2017) Jonathan Fisher et al. MOLECULAR THERAPY
- Sensing Bad: Are Co-stimulatory CAR-Expressing γδ T Cells Safer?
- (2017) Robin Parihar MOLECULAR THERAPY
- Function of Novel Anti-CD19 Chimeric Antigen Receptors with Human Variable Regions Is Affected by Hinge and Transmembrane Domains
- (2017) Leah Alabanza et al. MOLECULAR THERAPY
- Donor CD19 CAR T cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity
- (2017) Arnab Ghosh et al. NATURE MEDICINE
- CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy
- (2017) Terry J Fry et al. NATURE MEDICINE
- CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells
- (2017) Levi J. Rupp et al. Scientific Reports
- Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment
- (2017) Oladapo O. Yeku et al. Scientific Reports
- Tonic 4-1BB Costimulation in Chimeric Antigen Receptors Impedes T Cell Survival and Is Vector-Dependent
- (2017) Diogo Gomes-Silva et al. Cell Reports
- mSA2 affinity-enhanced biotin-binding CAR T cells for universal tumor targeting
- (2017) Jason J. Lohmueller et al. OncoImmunology
- CAR T-cell intrinsic PD-1 checkpoint blockade: A two-in-one approach for solid tumor immunotherapy
- (2017) Nan Chen et al. OncoImmunology
- Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells
- (2016) Omkar U. Kawalekar et al. IMMUNITY
- Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study
- (2016) Alexander M. Lesokhin et al. JOURNAL OF CLINICAL ONCOLOGY
- Co-infusion of haplo-identical CD19-chimeric antigen receptor T cells and stem cells achieved full donor engraftment in refractory acute lymphoblastic leukemia
- (2016) Bo Cai et al. Journal of Hematology & Oncology
- Phase 1 clinical trial demonstrated that MUC1 positive metastatic seminal vesicle cancer can be effectively eradicated by modified Anti-MUC1 chimeric antigen receptor transduced T cells
- (2016) Fengtao You et al. Science China-Life Sciences
- Early memory phenotypes drive T cell proliferation in patients with pediatric malignancies
- (2016) Nathan Singh et al. Science Translational Medicine
- An adenoviral cancer vaccine co-encoding a tumor associated antigen together with secreted 4-1BBL leads to delayed tumor progression
- (2016) Emeline Ragonnaud et al. VACCINE
- Improved anti-leukemia activities of adoptively transferred T cells expressing bispecific T-cell engager in mice
- (2016) X Liu et al. Blood Cancer Journal
- Third-generation CD28/4-1BB chimeric antigen receptor T cells for chemotherapy relapsed or refractory acute lymphoblastic leukaemia: a non-randomised, open-label phase I trial protocol
- (2016) Xiao-Yi Tang et al. BMJ Open
- Gp96-Ig/Costimulator (OX40L, ICOSL, or 4-1BBL) Combination Vaccine Improves T-cell Priming and Enhances Immunity, Memory, and Tumor Elimination
- (2016) G. Fromm et al. Cancer Immunology Research
- Fine-tuning the CAR spacer improves T-cell potency
- (2016) Norihiro Watanabe et al. OncoImmunology
- Murine allogeneic CD19 CAR T cells harbor potent antileukemic activity but have the potential to mediate lethal GVHD
- (2015) E. Jacoby et al. BLOOD
- TRUCKs: the fourth generation of CARs
- (2015) Markus Chmielewski et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16ecto directed chimeric antigen receptors for recurrent ovarian cancer
- (2015) Mythili Koneru et al. Journal of Translational Medicine
- CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia
- (2015) S S Kenderian et al. LEUKEMIA
- 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors
- (2015) Adrienne H Long et al. NATURE MEDICINE
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
- (2015) Stephen M. Ansell et al. NEW ENGLAND JOURNAL OF MEDICINE
- IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumorsin vivo
- (2015) Mythili Koneru et al. OncoImmunology
- ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells
- (2014) S. Guedan et al. BLOOD
- Interleukin-7 Mediates Selective Expansion of Tumor-redirected Cytotoxic T Lymphocytes (CTLs) without Enhancement of Regulatory T-cell Inhibition
- (2013) S. K. Perna et al. CLINICAL CANCER RESEARCH
- Persistence and Efficacy of Second Generation CAR T Cell Against the LeY Antigen in Acute Myeloid Leukemia
- (2013) David S. Ritchie et al. MOLECULAR THERAPY
- Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning
- (2012) H. J. Pegram et al. BLOOD
- Local Delivery of lnterleukin-12 Using T Cells Targeting VEGF Receptor-2 Eradicates Multiple Vascularized Tumors in Mice
- (2012) D. Chinnasamy et al. CLINICAL CANCER RESEARCH
- CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo
- (2011) D.-G. Song et al. BLOOD
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now